Conference Correspondent

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

Conference Correspondent - ASH 2018 - CLL
To date, the role of minimal residual disease (MRD) status as a predictive factor for progression-free survival (PFS) has only been established following chemoimmunotherapy. At the ASH 2018 Annual Meeting, researchers presented an analysis of peripheral blood (PB) MRD kinetics in relation to PFS after patients had completed therapy.

In the study, patients were randomized to venetoclax plus rituximab (VenR) or bendamustine plus rituximab (BR). Response was assessed clinically using complete blood count and physical examination at follow-up visits. PB MRD was analyzed centrally by allele-specific oligonucleotide polymerase chain reaction and/or flow cytometry at cycle 4, end of combination therapy, and every 3 months thereafter until 3 years, then every 6 months. Median follow-up was 36.0 months.

VenR patients achieved higher PB undetectable MRD (uMRD) rates (62%) compared with BR (13%) when combination therapy was completed. Likewise, observed uMRD rates were substantially different through month 24, when venetoclax single-agent treatment was scheduled to cease: 48% uMRD in VenR versus 2% in BR. Furthermore, consistently high uMRD rates were observed in all VenR subgroups, including patients with high-risk cytogenetics and molecular factors. Landmark analysis of PFS by MRD status in PB at the end of combination treatment response visit showed that MRD status was associated with longer PFS. At 2 years, 130 patients in the VenR arm completed treatment without disease progression. Of these patients, 83 (64%) were uMRD.

The data demonstrate the value of PB MRD as a predictive marker of clinical outcome for the chemotherapy-free regimen VenR, and confirm that the MRD rate is a meaningful end point for future research endeavors.

Kater AP, et al. ASH 2018. Abstract 695.

Related Items
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
Conference Correspondent published on December 2, 2018 in ASH 2018 - CLL
Last modified: December 4, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME